Guanglei Li

Title: Guanglei Li: Innovator in Tumor-Specific Polypeptides

Introduction

Guanglei Li is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of cancer research through his innovative work on tumor-specific polypeptides. With a total of three patents to his name, Li is recognized for his dedication to advancing medical science.

Latest Patents

Li's latest patents include groundbreaking inventions that focus on tumor-specific polypeptides. One of his notable patents is titled "Tumor-specific polypeptide and use thereof." This invention relates to a novel tumor-specific polypeptide that exhibits high affinity for HLA-A0201 and possesses cytotoxic T lymphocyte inducing ability. It is particularly useful for diagnosing, preventing, and treating diseases associated with high expression or mutations in the TWISTNB gene. Another significant patent is "CACNA1H-derived tumor antigen polypeptide and use thereof." This patent provides a tumor antigen polypeptide with a specific amino acid sequence, along with various applications in the diagnosis, prevention, and treatment of cancers.

Career Highlights

Guanglei Li is currently employed at Genoimmune Therapeutics Co., Ltd., where he continues to push the boundaries of cancer research. His work has garnered attention in the scientific community, and he is recognized for his innovative approaches to tackling complex medical challenges.

Collaborations

Li collaborates with esteemed colleagues such as Yong Hou and Shuntao Luo. Their combined expertise contributes to the advancement of research and development in the field of immunotherapy.

Conclusion

Guanglei Li's contributions to the field of tumor-specific polypeptides highlight his role as a leading inventor in cancer research. His innovative patents and collaborations reflect his commitment to improving medical outcomes for patients.